← Russell 3000 cross-section

CTMX CytomX Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$732m
Revenue TTM
$18m
Net income TTM
$-80m
Free cash flow
$-82m
Composite score
39.1
Sector rank
#2205

Valuation

P / E
EV / EBITDA
EV / sales
21.9
FCF yield
-11.27%
Earnings yield vs 10-yr
-15.62pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-435.2%
EBITDA margin
ROE
-26.4%
ROIC
Revenue growth
-87.0%

Insider activity, last 90 days

Net open-market
$-0.00m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net Income (Loss) Per Share Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. As a result, a cumulative adjustment of $ 7.1 million of revenue was recognized in the first quarter of 2026, which lowered the net loss per share by $ 0.04 for the six months ended June 30, 2026 . As of June 30, 2026, there was no deferred revenue relating to the Astellas Agreement. Deferred revenue was $ 8.6 million as of December 31, 2025. …CytomX Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →